News Caplin Point Laboratories Limited NSE India S.E.

Stocks

CAPLIPOINT

INE475E01026

Pharmaceuticals

Market Closed - NSE India S.E. 04:35:07 04/09/2026 pm IST			5-day change	1st Jan Change
2,810.80 ^INR	-1.20%		+10.63%	+52.92%

15/08	Caplin Point Laboratories Limited, Q1 2027 Earnings Call, Aug 12, 2026
12/08	Caplin Point Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2026	CI

All News

Mentions Relevance

15/08	Caplin Point Laboratories Limited, Q1 2027 Earnings Call, Aug 12, 2026
12/08	Caplin Point Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2026	CI
12/08	Caplin Point Laboratories Limited Recommends Final Dividend for the Financial Year Ended March 31, 2026, Payable on or Before October 24, 2026	CI
15/05	Caplin Point Laboratories Limited, Q4 2026 Earnings Call, May 14, 2026
15/05	Caplin Point Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026	CI
14/05	Caplin Steriles Limited Gets Usfda Approval for Foscarnet Sodium Injection	CI
14/05	Caplin Point Laboratories' Consolidated Profit Rises in Fiscal Q4; Shares Jump 10%	MT
14/05	Caplin Point Laboratories March-quarter consol net profit 1.7 bln rupees	RE
05/05	Caplin Point Laboratories Unit Gets US FDA's Final Nod for Calcium Gluconate Injection	MT
13/03	Caplin Point Laboratories Unit Gets US FDA's Nod for Potassium Phosphates Injection	MT
13/03	Caplin Point Laboratories unit receives final USFDA approval for ANDA potassium phosphates injection	RE
03/03	Caplin Point Laboratories Limited Announces Cessation of C K Gariyali as Independent Director, with Effect from the Close of Business Hours on March 03, 2026	CI
24/02	Caplin Point Laboratories Arm Gets US FDA's Final Approval for Sodium Phosphates Injection	MT
24/02	Caplin Point Laboratories says unit receives USFDA approval for sodium phosphates injection	RE
06/02	Caplin Point Laboratories Limited, Q3 2026 Earnings Call, Feb 05, 2026
05/02	Caplin Point Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025	CI
05/02	Caplin Point Laboratories Dec-quarter consol net profit 1.64 billion rupees	RE
03/02	Caplin Point Laboratories Limited Announces Changes to Its Board	CI
27/01	Caplin Point Laboratories unit receives USFDA approval for methylprednisolone acetate	RE
09/12	Caplin Point Laboratories Gets US FDA Nod for Linezolid Injection	MT
09/12	Caplin Point Laboratories unit gets USFDA final approval for Linezolid Injection, Infusion bags	RE
08/12	Caplin Point Laboratories unit receives final US FDA approval for its ANDA Acetaminophen Injection	RE
06/11	Caplin Point Laboratories Limited, Q2 2026 Earnings Call, Nov 06, 2025
05/11	Caplin Point Laboratories appoints Ashok Partheeban as vice-chairman	RE
05/11	Caplin Point Laboratories Limited Announces Executive Changes , Effective November 5, 2025	CI